Rodman & Renshaw initiated coverage on shares of Monopar Therapeutics (NASDAQ:MNPR – Free Report) in a report published on Friday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $50.00 target price on the stock.
Separately, HC Wainwright raised their price target on Monopar Therapeutics from $2.00 to $6.00 and gave the company a buy rating in a report on Wednesday, August 14th.
Get Our Latest Analysis on Monopar Therapeutics
Monopar Therapeutics Price Performance
Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last announced its quarterly earnings results on Friday, August 9th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). As a group, analysts expect that Monopar Therapeutics will post -1.93 EPS for the current year.
About Monopar Therapeutics
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
See Also
- Five stocks we like better than Monopar Therapeutics
- Energy and Oil Stocks Explained
- Why Fastenal Stock Could Hit New Highs After Strong Q3 Results
- What is Short Interest? How to Use It
- Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
- How to Invest in Blue Chip Stocks
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.